CFGI’s Post

Streamlining finance processes when going public is a momentous occasion for any life sciences or biotechnology company, but the road to an IPO is littered with obstacles. Sticking to your IPO timeline can be difficult unless every team member plays their part to perfection and anticipates SEC requirements from the outset. Download our FREE case study eBook and talk to a CFGI partner today! 🙌🏻

When it's time for your life scienecs or biotechnology company to go through the IPO process, you should be prepared: Getting to the crowning achievement of an IPO requires overcoming a variety of potential obstacles. Our eBook gives you all the insights you need for a painless IPO. Read up now: https://bit.ly/3ENmVIU #CFGI #LifeSciences #IPO #GoingPublic

Initial public offerings (IPOs) are a critical step in the capital formation path for the #biotech industry, providing companies with the public capital they need to advance to their next phase of growth. Considering a 2024 #IPO? One of the crucial elements of IPO preparedness is developing your SEC Form S-1. Delivering a document that effectively tells your corporate story is key to a successful outcome for your IPO process.  Learn how MacDougall can support your S-1 Form writing: bit.ly/3ravYQV Questions? Reach out to our team: inquiries@macdougall.bio  #scicomms #lifesciences

Download our eBook to learn how CFGI takes U.K. companies through the IPO readiness process, streamlining their timeline to going public: https://bit.ly/3o4wcTx #CFGI #IPO #SPAC #UK #GoingPublic #IPOreadiness #PubliclyTraded

Download our FREE case study eBook and talk to a CFGI partner today! 🙌🏻

🚀 IPO Alert! Concord Biotech Ltd. 🚀 Rakesh Jhunjhunwala’s - backed Concord Biotech Ltd. (CBL), a bio-pharma company is coming up with an IPO to raise around Rs. 1,550cr, which opens on 4th Aug and closes on 8th Aug. 2023. The price band is Rs. 705 - 741 per share. 🌟 💼The IPO only has an OFS portion, thus the company will not receive any proceeds from the issue. Promoter & promoter group and public currently have 44.08% and 55.92% stake in the company, which will remain unchanged post-IPO. Date - 4th to 8th August 2023 IPO Details 📊 : Price Band: ₹705 - ₹741 per share Number of shares per lot: 20 Min Investment : Rs14,820 per lot Watch the video 📹 to know more about it and for more informative 📚 content follow Choice 👉 Choice Equity Broking Private Limited - Research Analyst (SEBI Reg. No. INH000000222) 👉For disclaimer and disclosure please refer the link - https://lnkd.in/dDhZC7xV 👉 Disclaimer: Investment in the securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. . . . #IPOAlert #iponews #IPO #ConcordBiotech #Choice #TheJoyOfEarning

Expect more reverse mergers in biotech before year's end. This week's showings — Graphite Bio + Lenz Therapeutics and Homology Medicines + Q32 Bio — are likely just the beginning as the IPO path remains icy. “We really saw companies lining up for the fourth quarter and going out and also accelerating timelines, and that all really slowed down after the outbreak of the war because people were unsure what was going to happen,” Jordan Saxe, head of healthcare listings at Nasdaq, told Endpoints News. “That pause was just enough to slow down the market at the end of the year where we had just started to get some momentum.” Saxe foresees about five to eight listings in the first quarter of 2024, with next year looking "very similar to this year, but maybe a slight uptick" in IPOs for the industry. Drug developers looking to go public are facing stiff walls on Wall Street as the go-go period of 2020 and 2021 is far in the rearview. #biotech #ipo #initialpublicoffering #nasdaq #lifesciences #drugdevelopment #startup #venturecapital #biopharma #wallstreet #reversemerger #mergers

Are you a U.K. biotech stakeholder interested in harnessing the low volatility and large investor pool of the U.S. IPO market? There are a few hurdles to clear before you can close your transaction, and our eBook lays out the best approach to overcoming them. Read it now: https://bit.ly/450kZHp #CFGI #UK #Biotech #GoingPublic #IPO

Are you planning to take your life sciences company public? This is a big move, one that demands intensive planning and preparation. You need to perform all the usual due diligence of a standard IPO, combined with extra oversight to make sure you're meeting all the regulatory requirements for your field. In our guide, we lay out everything you need to know, step by step. Check it out and make sure you're prepared: https://bit.ly/4bC199Q #CFGI #LifeSciences #IPO #GoingPublic

UK Biotech IPO An IPO in the U.S. market may look very appealing to your U.K. biotech company, but what about the procedural barriers that make the process challenging? Our experts have experience with this complex process and have put together a step by step guide. Please reach out to us if you would like to hear how CFGI can support you on your IPO journey. Read our eBook to see how it works: https://bit.ly/450kZHp #CFGI #UK #IPO #Biotech #GoingPublic